1-18 of 18
Mark D. Pegram
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer

Xavier Pivot, Mark D Pegram, Javier Cortes, Diana Lüftner, Gary H Lyman, Giuseppe Curigliano, Igor M Bondarenko, Mikhail Dvorkin, Jin Hee Ahn, Seock-Ah Im, Maria Litwiniuk, Yaroslav V Shparyk, Gwo Fuang Ho, Nikolay V Kislov, Marek Wojtukiewicz, Tomasz Sarosiek, Yee Soo Chae, Jin Seok Ahn, Hyerin Jang, Sujung Kim, Jiwon Lee, Soo Young Lee, Ye Chan Yoon
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P2-13-04
Published: 15 February 2022
View article
Journal Articles

Abstract OT1-10-01: The Breast Cancer Index registry study: A prospective multi-center observational study to evaluate patient outcome, clinical impact, and medication adherence in HR+ breast cancer patients considering treatment with extended endocrine therapy

Joyce A O'Shaughnessy, Jenny R Fox, Carlos A Encarnación, Brandon O'Neal, Kai Treuner, Tara Sanft, Rachel C Jankowitz, Mark D Pegram, Catherine A Schnabel, Sami G Diab
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-10-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT1-10-01
Published: 15 February 2022
View article
Journal Articles

Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis

Hope Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N. Schwartz, Timothy Pluard, Francesco Ricci, William Gwin, III, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Emily Ashley, Shengyan Hong, Minori Rosales, William J. Gradishar
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD8-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD8-01
Published: 15 February 2022
View article
Journal Articles

Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors

Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Arielle L. Heeke, Ding Wang, Lawrence Garbo, Sudhir Manda, Jasgit Sachdev, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Amreen Husain, Edith A. Perez, Ecaterina Ileana Dumbrava
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT218.
DOI: https://doi.org/10.1158/1538-7445.AM2021-CT218
Published: 01 July 2021
View article
Journal Articles

Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer

Javier Cortes, Fatima Cardoso, Giuseppe Curigliano, William J Gradishar, Seock-Ah Im, Hope S Rugo, Shakeela W Bahadur, Alfredo Falcone, Serafin Morales Murillo, David A Riseberg, Antonino Musolino, Trevor M Feinstein, Miguel H Abreu, Young-Hyuck Im, Yelena Novik, Timothy Pluard, Lupe G Salazar, Rossana Berardi, Viorela Pop, Shengyan Hong, Kenneth Jacobs, Edwin Rock, Mark D Pegram
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS10-24.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS10-24
Published: 15 February 2021
View article
Journal Articles

Abstract PS10-12: Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC)

Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Mark D. Pegram, Hope S. Rugo, Ursa Brown-Glaberman, Denise A. Yardley, Sung-Bae Kim, Maaike de Boer, Zbigniew Nowecki, Vesna Glavicic, Ido Wolf, Nele Claes, Joo Hyuk Sohn, Thomas Bachelot, Peter A. Kaufman, Jan Baughman, Shengyan Hong, Kenneth Jacobs, Edwin Rock, William J. Gradishar
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS10-12.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS10-12
Published: 15 February 2021
View article
Journal Articles

Abstract PS17-06: Humanized anti-CD47 monoclonal antibody magrolimab (Hu5F9-G4) plus trastuzumab potentiates antibody-dependent cellular phagocytosis (ADCP), and cooperate to inhibit human HER2+ breast cancer (BC) xenografts growth in vivo

Rosalynd Upton, Dongdong Feng, Allison M Banuelos, Tanuka Biswas, Stephen Willingham, Kevin S Kao, Kelly McKenna, Benyamin Rosenthal, Michal C Tal, Jens-Peter Volkmer, Mark D Pegram, Irving L Weissman
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS17-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS17-06
Published: 15 February 2021
View article
Journal Articles

Abstract PS17-17: cGAS-STING pathway protein expression in human primary breast cancer

Yu Zong, Xiaofei Liu, Glen N Barber, Mark D Pegram
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS17-17.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS17-17
Published: 15 February 2021
View article
Journal Articles

Abstract PS9-11: Health-related quality of life for margetuximab + chemotherapy vs. trastuzumab + chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+ metastatic breast cancer

Fatima Cardoso, Javier Cortes, William Gradishar, Seock-Ah Im, Mark D. Pegram, Hope S. Rugo, Gail S. Wright, Michelino De Laurentiis, Christelle Levy, Jean-Marc Ferrero, Janine Mansi, Raul Oyola, Francesco Ricci, Erik H. Jakobsen, Beatriz Uziely, Daniel Egle, Aristoteles Giagounidis, Kirstin Williams, Shengyan Hong, Edwin Rock, Giuseppe Curigliano
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS9-11.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS9-11
Published: 15 February 2021
View article
Journal Articles

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Ecaterina Ileana Dumbrava, Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Shirish M. Gadgeel, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Antoinette R. Tan, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Edith A. Perez
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-03-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-OT-03-02
Published: 15 February 2021
View article
Journal Articles

Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis

Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Mark D. Pegram, Antonino Musolino, Thomas Bachelot, Gail S. Wright, Michelino De Laurentiis, Peter A. Kaufman, Timothy Pluard, Francesco Ricci, Lupe G. Salazar, Denise A. Yardley, Sutton Edlich, Shengyan Hong, Edwin Rock, William J. Gradishar, SOPHIA Study Group
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS1-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-GS1-02
Published: 15 February 2020
View article
Journal Articles

Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results

William J. Gradishar, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Mark D. Pegram, Antonino Musolino, Rosanna Berardi, Michelino De Laurentiis, Shakeela W. Bahadur, Young-Hyuck Im, Cynthia Lynch, Yelena Novik, Sutton Edlich, Edwin Rock, Shengyan Hong, Hope S. Rugo, SOPHIA Study Group
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P1-18-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P1-18-04
Published: 15 February 2020
View article
Journal Articles

Abstract 2123: Antibody-dependent cell-mediated cytotoxicity (ADCC) tolerance to monoclonal antibody therapeutics in human breast and colon cancer cell lines

Tanuka Biswas, Rebecca Fritzemeier, Adam Mark, Tobias Meißner, Brandon M. Young, Mark D. Pegram
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2123.
DOI: https://doi.org/10.1158/1538-7445.AM2016-2123
Published: 15 July 2016
View article
Journal Articles

Abstract 2018: Investigation of ITAF's role in the pathophysiology of breast cancer

Jessica Bockhorn, Toby M. Ward, J. Chuck Harrell, Xiaofei Liu, Gaby Fuchs, Mark D. Pegram
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2018.
DOI: https://doi.org/10.1158/1538-7445.AM2016-2018
Published: 15 July 2016
View article
Journal Articles

Abstract 352: HER2 protein isoform heterogeneity investigated by single-cell western blotting

Ginny (Chi-Chih) Kang, Toby M. Ward, Jessica Bockhorn, Mark D. Pegram, Amy E. Herr
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 352.
DOI: https://doi.org/10.1158/1538-7445.AM2016-352
Published: 15 July 2016
View article
Journal Articles

Abstract 1715: IRES-transactivating factors (ITAFs) as therapeutic targets in breast and colorectal cancer

Toby M. Ward, Jessica Bockhorn, J C. Harrell, Xiaofei Liu, Mark D. Pegram
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1715.
DOI: https://doi.org/10.1158/1538-7445.AM2015-1715
Published: 01 August 2015
View article
Journal Articles

The role of Insulin-like Growth Factor I Receptor (IGF-IR) in Trastuzumab resistance in breast cancer cells

Brigid C. Browne, Norma O’Donovan, Natarajan Venkatesan, Mark D. Pegram, Martin Clynes, Michael J. Duffy, John Crown, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 288–289.
Published: 15 April 2006
View article
Journal Articles

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Gottfried E. Konecny, Mark D. Pegram, Natarajan Venkatesan, Richard Finn, Guorong Yang, Martina Rahmeh, Michael Untch, David W. Rusnak, Glenn Spehar, Robert J. Mullin, Barry R. Keith, Tona M. Gilmer, Mark Berger, Karl C. Podratz, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2006) 66 (3): 1630–1639.
DOI: https://doi.org/10.1158/0008-5472.CAN-05-1182
Published: 01 February 2006
View article
PDF